Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 939-253-5
CAS number: 68424-85-1
For result tables, kindly refer to the
attached background material section of the IUCLID.
study was conducted to determine the inhalation acute inhalation
toxicity of a mixture of test substances (77.3% total active) containing
cocobenzyldimethylamonium chloride (C12-16 ADBAC; 40% active) and
dicocodimethylammonium chloride (di C12-16 DMAC; 37.5% active),
according to OECD Guideline 403 and US EPA OPP 81 -3, in compliance with
GLP. The experiment was performed in Sprague-Dawley rats. Four groups of
ten rats (five males and five females) were given a single, 4 h whole
body exposure at concentration levels of 0, 0.17, 0.24 and 0.34 mg/L.
The animals were observed for 21 d after exposure and were then culled
for gross and histopathological examination of the lungs. Bodyweight,
food and water intake and lung weight were also determined. There were
no deaths in the control group; one animal (male) died at 0.17 mg/L,
four animals died at 0.24 mg/L (3 males, 1 female), and nine animals
died at 0.34 mg/L (5 males, 4 females). Clinical signs of toxicity noted
were (partial) closing of the eyes and exaggerated respiratory movement
during exposure in all test groups, gasping and wetness around the mouth
during exposure at 0.34 mg/L. Clinical signs were noted in survivors
throughout the 21-day observation period. A decrease in body weight
reduced weight gain, and reduced food and water intake were generally
seen up to Day 14. Abnormalities noted at necropsy in survivors were
increased relative lung weight, swollen appearance of the lungs and
gas-filled stomach and intestines. Animals that died showed congestion
of the lungs, fluid in the trachea, and gas-filled stomach.
Histopathological lung changes in survivors generally consisted of focal
alveolitis and bronchiolitis; changes in deceased animals generally
consisted of focal alveolar wall necrosis, diffuse congestion, focal
alveolar wall oedema and focal alveolar wall haemorrhage. Under the
study conditions, the 4 h LC50 of the test substance was calculated to
be 0.25 mg/L or 250 mg/m3 (95% CI: 0.22-0.28 mg/L or 220-280 mg/m3) i.e.,
equivalent to 129 mg/m3 for
C12-16 ADBAC (Jackson,
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Tällä verkkosivustolla käytetään evästeitä parhaan mahdollisen käyttäjäkokemuksen varmistamiseksi.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Do not show this message again